EFTA00299745.pdf

BioReference LABORATORI ES en OPKO Health Cur.peny ER, STUART C3070 - STUART ORSHER, K.D. 9 EAST 79TH ST, NEW YORK, NY 10021 Acct 4: C3070 P: MO IA EPSTEIN, JEFFREY 00B: 01/20/1553 Age: 64 V Sex: M U/FL: Bed; Re: Patient ID: ddress:9 EAST 71ST STREET, NEW YORK, Me 10821 v: Notes: NON FASTING FINAL REPORT Specimen ID: 104364919 Date Of Report: en/00/2017 1.1:34 pate Collected: 08/10/1017 11:58 Date Received: 08/10/2917 23:12 North Amrr-::co Ejitcrr rime: CLINICAL REPORT Unita). Abnormalities Elcnnmcarif (May not contain all abnormal results; narrative results may not have abnormal flags. eicaSe review entire report.) Glucose Cholesterol TgG HAND 41 Hemoglobin A1C CK ANA TITER (IFA) PNEUMO Ab TYPE 8 (58) PNEUMO Ab TYPE 19 (58) PNEUMO Ab TYPE 56 (58) 185 HI 226 HI Positive • 5.7 HI 346 MI 1:160 HI 0.4 (19F) 0.8 (16C) 1.3 (58) LO PPFumo Ab TYPE 9 (9N) 0.4 LO (58) LO PNEUMO Ab TYPE 23 (23F) (58) LO PNEUMO Ab TYPE 68 (9v) 0.4 LO LD Triglycerides HERPES I Ab.(IgG) 235 HI 1510 HI 7.40 MI HERPES II Ab.(IgG) CHLAMYDIA AB. IgG/IgM SEE BELOW • ANA SCREEN (38) PNEUMO Ab TYPE 1 PNEUMO Ab (58) PNEUMO no (58) PRIMO Ab TYPE 2E0.5 LO (58) B.Henselae IgG At1:64 • (58) (3) Total Protein 7.3 5.9-8.4 g/dL ridbuldil .. I 4:4 . I -g: TY . edl. i 7-jY g/FIL . . . . . _ .. -1-3 ----- -1.17 57i----- . ,. . . 105 HI 70-99 • • mg/dl. 140 135-147 mmol/L IA16 Arlo . Glucose : Sbifum . . .Potassiun 4.3 fa BUN 20 creatinine • • 0.91 88 iA-4EicAfricanCAdrican' • 102 >or-00 mumin 3.5-5.5 mmol/L . Amin 22-29 - ' 8-23 Mar.00 mL/min Cilciun- • 9.7 8.4-18.4. 'Uric Acid : . -Y:4 3.4,8.5 - Iron i 82 . • ss.lte litrlirartit- Totr e.s <1.2 LD 235 NI . 195.225 E s • • deciL " 5.70 HI Positive • TYPE 4 0.6 LO TYPE avdt • edi/di. . .mdidt • Cr - *fit BioReference Laboratories, Inc. 481 Edward H. Ross Dr I Elmwood Park. 87 07407 I James Weisberger M.D. Page 1 of IS Laboratory Director Printed 09/08/2017 16:22 EFTA00299745 BioReference APORATOR . E$ OPICO Health Company ORSHER, STUART C3070 - STUART ORSHER, N,.D. 9 EAST 79TH ST, NE4 YORK, NV 10021 Acct 4: (C3070) D. CLINICAL REPORT AST PHOSPHORUS !ALT 7 3.i <5 ----- • - EPSTEIY, 3EFFREY DOB: 31120/1153 Age: 64 y sex: M U/FL: Bee: tit Patient ID: Addrecs:o PAST 71ST STRUT, SE.: YORK, NY 10021 .4, • <41. NOTE: The result for ALT has been confirmed by repeat analysis. GGTP 23 10-71 FINAL REPORT a E Specimen ID: 104364919 Date Of Report: 09/00/2017 11:30 Date Collected:ea/xi/2017 11:$II Date Received: 06/300,2017 23:12 North Americo Eastern Ti.. U/L mg/dL — U/L CARDIOVASCULAR/LIPIDS *-- Cholesterol :Trigkmw404 i in The result for Triglycerides has been confirmed by repeat analysis. HDL CHOL., DIRECT Tup 226 NI 151VICI >40 <200 mg/dL <150 ii7ac mn/OL Test Not Performed: Unable to perform HDL test due to elevated Triglycerides (>1290). INDL airtof diolesterol. TNP >14 Chol/HDL Ratio TNP <7.4 0.0L/HOL' Ratio TNP <3.56 ibLthblesterol cib't tile <100 sox NOTE: Unable to calculate LDL due to a Triglyceride level of greater than 400 mg/dL. Aribc-tAtidAATE6 . CateCtillc. 14i" mg/ii i . • . can't Cale: one or more components was outside the measurable range. We are unable to calculate. • Test *Ida Perforad: One or more conponents were not available to percorm calculation. Iv HEMATOLOGY * WBC H6B MCV 6.10 5.15 15.4 417/ 85.4 3.66-11.99 4:24:37017- 12.3-17.6 08.8.100:0 x10(3)/uL .kligi57E1 gm/di-'' we ...DVS fL f4CH ---..,....- 29.9 35.0 if.0-34.1 29.0-35.8. ' PR glitch. ileir7 — - ..!-- - *--- . . Em. POLYS 46.9 36.0-T6S t ;OHMS . • . 39.0 .--- :54/1:9 :Alois _.. 7.7 . . . . . . 0.0-13.0 S BioReference Laboratories, Inc. JamosVhaisboroorbeD. Page 2 of IS 401 Edward H. Ross Dr i Elmwood Park: ND 07407 Laboratory Director printed 09/68(2617 16:22 EFTA00299746 BioReference FINAL REPORT I. A B ORATOR I ES on OPKOHHamh Company D 0 C 0 R GUSHER, STUART 03870 - STUART 'ASHER, N.D. 9 EAST 79TH ST, NEW YORK, NY 10021 Acct #: 03070) P: MO CLINICAL REPORT EOS . BASOS leeet 6RANULOCYiES 0.2 Platelet Count • 248 MPV 5.4 I EPSTEIN, 3EFFREY • DOO! 81/20/1953 Age: 04 Y Sex: M U/FL: Bed: Rs: Patient ID: eess:9 EAST 71ST STREET, NEW YORK, NY 10021 P: 9.6 Specimen ID: 104384919 Date Of Report:09/0812017 11:38 Date Collected: 08/30/2017 11:58 Date Received: 88/30/2017 23:12 North Americo Foltern Time 0.0-8.0 0.6-2.B > (.10.4.6 144.400 xi0(5)/uL 8.2-11.9 . -e -43:-.22:2-Ä-z-11":-777•77137: . • URINALYSIS Co or YELLOW YELLOW, STRAW, AMBER CLEAR 1.003-1.039 5.0-8.0 NEGATIVE WOW NEGATIVE 0.2-1.0 wg/dt NEGATIVE NEGATTir NEGATIVE NEGATIVE NONE NONE 8.4 NONE-PEW 0-4 0-1 0-1 • • • NONE:FEW character CLEAR .Specific Ori4.4,Y Or. " .1.019 Urehe 6.5 Oreteie-,-Üani • - • - - • 'iüdkiie-- • ketone, 'urine • NEGATIVE • ru o6ii nölten urine 0.2 ;Bilirunii, urine ' NEGATIVE !eleceet.urile • • • • aate-Ti— v e: !Crystals Urine :Wit; tWine ;Epithelial Cel7.s, Br ;cast, Nyaline, urine !teat; lust, ROC, urine. • . rinek-teria; Urine - NEGATIVE NEGATIVE • NEGATIVE NONE NONE 0;4 NONE SEEN • NONE 8-4 NONE SEEN NONE SEEN NONE PER fer PER HPF PER LPF PER LPF • • • PER LPF ' "‚i ir ROBIOLOGY !CULTURE, URINE • SITE: URINE NO GROWTH NO GROWTH LyrE W6, IgG W/BANDS T--- alp BAND 18 ,IgG RAND-26 rig& BAND 28 lie BAND 30 IgG BAND 39 IgG BANCO 41 IgG BAND 45 rfge. BAND S8 Negative Negative NegatfUe 'Negative • NegatiVe Negative Negative Negative Negative Positive • Negative Negative Negative NegitIVO Olt/Reference Laboratories, Inc. 481 Edward M. Roes Or I Elmwood Park, N) 07407 I kDa kDa kDa kDa kDa kDa kDa kDa Pap 3 of 15 Jamms1NoWsorgorht0. Laborstory Director printed 00/011/2017 16:22 EFTA00299747 BioReference LABORATORI E $ tin OPKci maim, Company PSTEIN, JEFFREY FINAL REPORT ORSHER, STUART Specimen ID: 204364919 P DOS: ex/20/1953 Age: G4 V Sek:M Date Of Report: 09/88/2017 11:30 C3070 - STUART ORSHER, M.D. A U/FL: Bed: Rm: A Date Collected: 08/30/2017 11:58 Date Received: 88/30/2017 23:12 9 EAST 79TH ST, I atient ID: NEW YORK, NV 10021 Acct e: (C3670) MO E N Address:9 EAST 71ST STREET, NEW YORK, NY 10021 P. P: North Amerit0 Ehnen, Time CLINICAL REPORT IgG WINO 66 . ' NOTEt LYMI ANTSCOY (Ige) by WESTERN BLOT is considered to be positive if any 5 but of the-following 20 bands are present: 18, 23, 28, 36, 39, 41, 45, 58, • 66, 93 1070. togatIve Negative Negative Negative • — kDa • ' Lyme Ig6 INTERPRETATION WE Negative Negative •-.F77:-7., 7: LYME WB, 1gM W/BANDS /81 BAND 23 Negative Negative le WO 39 Negative Negative IgM BAND 4a Indetermin Negative ItDa kDa kOa NOTE: LYME ANTIBODY (18K) by WESTERN BLOT is considered to be positive if any 2 out of the following 3 bands are present: 23, 39, 41 kDa. Lyme Iglu ~IITERPIIETATIOPI {d8 • • glegative Negative IgE, SERUM TNP _ . . Test Not Performed: Specimen is LIPEMIC. ALLERGEN INTERPRETATION: CONCENTRATION (kUA/L) <0.10 0.18 - 0.34 0.35 • 0.69 0.70 - 3.49 3.50 - 17.49 17.50- >200.80 Hemoglobin Alt i HEMOGLOBIN Ale AM) eA6 REFERENCE Ale(%) ‹S.7 5.7-6.4 e>6.5 INTERPRETATION Absent Very Low LOW Moderate High Very High RANGES Kor=114.0 0148ETES CATEGORY* Normal (non-diabetic) Increased risk of diabetes Consistent with diabetes kU/L Alc(%) aNEESTDATED AVERAGE PLASMA GL00061)(mg/dL) 6 126 7 154 8 183 9 212 10 240 11 269 298 81oReFerenee Laboratories, inc. 481 Edward H. Ross Dr I Elmwood Park, Hl 07407 I James Weisberger M.D. Page 4 of IS Laboratory Director Printed 09/08/2017 16:22 EFTA00299748 BioReference FINAL REPORT _ABORATOR I ES OPKOHAnith Company I ORSHER, STUART P C3070 - STUART ORSHER, M.D. 9 EAST 79TH ST, NEW YORK, NY 10021 cet 4: (C3070) : CLINICAL REPORT P A I N T .... _ EPSTEIN, 1EFFREY DOB: 01/20/1953 Age: 64 V Sex: M /FL: Bed: m: atient ID: Address:9 FAST 71ST STREET, NEW YORK, uY le021 *recommended ranges-American Dlabetes AssociaCion(2ea0) Specimen ID: 104364919 Date of Report:69/08/201711:39 Date Collected: eS/30/2017 11:S0 Date Received: 03/B9/2017 23:12 Mort', 4morico Eoltcrm Tlmr NOTE: The amount of glycated hemoglobin as measured by the HbAle test may be overestimated in African Americans and should not be used as the sole parameter of glycemic burden. Similarly, hemolysis, genetic hemoglobin variants and chemically modified hemoglobin derivatives (as seen in renal failure, smoking, aspirin use) may also affect glycated hemoglobin levels. A!0/Rh ltbf~ 'ME. .. . A Pas Troi. 6.1.78:4:5Je . . . . . . Test mot Performed: Specimen rejected for testing due to moderato or merked heeolysis. THYROXINE (T.25 ?HP 4.9-12.9 ug/WL I T3 OrrAki " INp. • F--._ 114fROXINE; FREE terT•• -ir TNP • 8.88-1.73 ng/dL FREE T4 INDEX TNP 1.5-3.8 rictilifitofaii)rilWAL !TIA.Iiiiiii-(5PEP) • • :ALPHA-1,61.0B. (SPEP) • Aiiiiik;i:EL66:($0E0)• iBE A GLIECOPEIT WARWELWAsiii0j .REiPIRE iSPEP GRATA 11441- nedi - • . . . 8.17-6.41 • gicir . . TNP . . TNP • • 8.42-6.99 TNP TNP 0.65-2.0 • g/dL - •-• TNP TNP See Graph • • NOTE: Specimen submitted is LIPEMIC. This may cause inaccurate results. Please RISUMMIT a fasting specimen at your earliest convenience. 'PERM* ; TNP 22-322 • ngimL ' tut roe Performed: Specimen rejected for testing due to moderate or marked . • • hemolysis. NEP. A Al.. TOTAL TNP Her.-WW11-,46:-Ukr TNP - - TIP . . . . • Non-Reactive NOsfleactive Non-Reactive Non:AisEfiim Negative g .. . . pip. BE !AG.. TNP Non-Reactive ' !INA, SERUM 225 . mg/dl. 70-488 rigGi :MIMI . e .' 1047 7Ro-W. - will . • . 3 QC jiff* -' - " " 46 '' 40-230 ..mg/dl !RCM . Non- Non-RfeetiVe Titer Reactive • •• • . - . • gioReference Laboratories, Inc. 481 Edward H. Ross Or I Elmwood Park, 63 07407 JamesWeisbergerNID. Page 5 of 15 LmbcwsdoriOlreclor Printed 09/08/2817 16:22 EFTA00299749 BioReference FINAL REPORT _ ,1 :7I RATOR I ES OPKO Health Company D 0 0 R ORSHER, STUART 3870 - STUART ORSHER, M.D. 9 EAST 79TH ST, NEW YORK, NY 10021 Acct a: (C3070) CLINICAL REPORT HERPES I AD. (tic) MO INTERPRETATION OF RESULTS FOR MSV-1 Antibody Index Result <0.90 AI Negative 0.90-1.89 AI Equivocal >or=1.10 AI Positive PSTEIN, 3EPFREY DOB: 01/20/1953 Age: 64 y Sex: ti /FL: Bed: Rm: Patient ID: Address:9 EAST 71ST STREET, NEW YORK, NY 10021 T N T P: 7.49 NI <0.99 AND HSV-2 Ig6 ANTIBODY Interpretation No HSV-IgG antibody detected Equivocal result. Repeat in 4-6 weeks IgG antibody detected A p E Specimen ID: 164364919 Date Of Report: 09/08/2017 11:50 Date Collected: 08/30/2817 11:58 Date Received: 08/30/2017 23:22 earth America Eastern Time e•ocorment:This assay is type specific and will differentiate between Herpes Simplex 1 and 2 infections. Test results should be interpreted in conjunction with clinical history. The performance of this assay has not been established for pediatric populations, for neonatal screening or for testing the imeunocompromised. HERPES II Ab.(IgG) S.76 HZ .0.9e Al INTERPRETATION OF RESULTS FOR HSV-1 AND NSV-2 IgG ANTIBODY Antibody Index Result Interpretation <e.g. Al Negative No RSV-In antibody detected 0.90-i.09 AI Equivocal Equivocal result. Repeat in 4.6 weeks ›orm1.10 Al Positive Ig6 antibody detected **.*Conment:Thi•s else), is type specific and will differentiate between Herpes Simplex 1 and 2 • infections. Test results should be interpreted in conjunction with clinical histOry. ' The performance of this assay has not been established for pediatric populations, fer neonatal screening or for testing the lemunocompromised. 193.07744.e . . NOTE: Patients receiving the drug Nandrolone cannot be tested for TESTOSTERONE, total using the ESA method (test code 0379-8) due to a strong interference from the drug. Clinicians are asked to request Testosterone, Total by LC/F6/06 (test code 3451-6) for these patients. a. IH.PYLORI Ab.,Ige iN.PYLORI Ab.,IgA .... ... .... _ ...._ . _ H. PYLORI Ab ., Teri TE4i-d- fkAgE Ab. F.44 <0.41 riabesia isicroiriiiiiPA(9) <1:20 -.'" '-' '' areilb sinIcea si) • <1:64 <1:64 Sera free patients aboon to have been infected by other tick-borne , pathogens, tabesii4uncani, Rickettsia rickettsii and Borrelia burgdorfiri, were screened and found negative by the B. microti /gG IFA. This test was, developed and its performance characteristics determined by 1 Viraoor:EurofinS. It has not been cleared or approved by the U.S. Food and —DrugAdainiatretion. BAG 10 19-399 0.34 See Below 9.49 — wee Below I Testing!PerfOrmed At: Viracor Eurofine BioReforenbe Laboratories, Inc. 481 Edward H. Ross Or I Elmhood Park, N; 07407 I James Welsbergar M.O. Page 6 of 15 Laboratory Director Printed 09/98/2017 16:22 EFTA00299750 BioReference FINAL REPORT AgoRATOR I 65 on OPKOHealUi Company I ORSHER, STUART C3070 - STUART ORSHER, H.D. 9 EAST 79TH ST, NEW YORK, NV 10921 Acct 4: (C3070) P: 1001 NW Technology Drive Lee's Siltrit, MO 64086 (see) 385-5198 CLIAlt 26O-0983643 Tetanus Antibody IgG (58) • . . . "This test was developed and Viracor Eurofins. It has not : Drug Administration. ' Testing Performed At: • Viracor Eurofins 1001 Nw Technology Drive Lee'sSummit MO 64086 ILIJIIIIIii 20D-0983643 EPSTEIN, 3EFFRET DOB: 01/20/1953 Ap: 64 V Sex: m U/FL: Bed: Rm: Patient ID: Address:9 EAST 71ST STREET, NEW YORK, NY 10021 1.37 >0.1 its performance characteristics determined by been cleared or approved by the U.S. Food and Diphtheria Antibody /gG(58) 0.31 >0.1 Testing Performed At: Viracor Eurofins ' 1081 NN Technology Drive Lee's Summit, MO 64086 CLIA* 26o-0983643 HIV Ag/Ab • • • TWO Non-ReaCtive Test Not Performed: Unable to perform HIV testing, specimen is LIPEMIC. • Assay Information: Assay for the detection of HIV p24 antigen and antibodies to Human IMANnodeficiency Virus Type 1,including Group 0 {HIV-1 + "0") and/or Type 2 (HIV-2) Method: Chemiluminescence (Siemens Healthcare Diagnostics) oey- SEE BELOW • C. pneumcniae IgM Titer <1:20 <1:20 C. trach IgM Titer <1:28 <1:20 C. psittaci IgM Titer <1:20 <1:20 C. pneunoniae IgG Titer 1:12* H <1:64 E. trach IgG Titer 4:64 <1:64 G. psittaci IgG Titer <1:64 <1:64 --INTERPRETIVE TIIFORMATION: C. psittaci IgG Titer --The rhlanydia antibody test contains both species- and genus- --specific antigens, and serological cross-reactions so be seen in mieeeference Laboratories, Inc. 461 Edward H. Ross Or I Elmwood Park, N3 07407 I Specimen ID: 104364919 Date Of Report: 00/08/2017 11:30 to Collected: 08/30/2017 11:58 Date Received: 08/30/2017 23:12 north Amtrica Eastern Time James Wrist:tenter M.D. Page 7 of 15 Laboratory Director Printed 09/0U2017 16:21 1 EFTA00299751 BioReference FINAL REPORT ASCaATPR I ES nn OPKO Mnnhth Company ORSHER, STUART C3078 - STUART ORSHER, M.D. 9 EAST 79TH ST, NEW YORK, NY 10021 Acct (C3070) P: EPSTEIN, JEFFREY DOB: 01/20/1953 Age: 64 y Sex: m U/FL: Bed: Rm: Patient ID: ress:9 EAST 71ST Steer, NEW YORK, Ny 10021 oth acute and conva escent seep es (less t an 1:128 . A C. --pneumoniae-specific reaction will exhibit titers twofold or --greater than titers observed with the C. trachomatis or C. • --psittaci serology. Any IgG titer may indicate past exposure to --that particular species. IgG titers in recently infected --indiyiduals are typically grater than or equal 1:512. --The Chlamydia microimemnefluOrescent assay slides utilize C. --psittaci, C. petymeniae, and nine serotypes of C. trachomatis. The --LGV strains of C. trachomatis are not included in this assay. --Test developed and characteristics determined by OUP --Laboratories. See Compliance Statement 4: aruplab.com/CS --www.aruplab,com, Julio Delgado, MD - Lab. Director QUINTANA Affdik (30) SEE BELOW B. quintana Ab, IgM < 1:16 --INTERPRETIVE INFORMATION: Bartonella quintana Ab, Ism -- Less than 1:16 Negative-No significant level of Bartonella quintana Igg antibody -- detected. -- 1:16 or greater Positive-Presence of IgM antibody -- to Bartonella quintana detected, -- suggestive of current or recent -- infection. --The presence of Igm antibodies suggests recent infection. Low --levels of 'gm antibodies may occasionally persist for more than 12 --months post-infection. --Test developed and characteristics determined by AAUP --Laboratories. Se. Compliance statement A: aruplab.com/CS --44w.aroPlab.com, Julio Delgado, MD - Lab. Director B. quintana Ab, IgG <1:64 --INTERPRETIVE INFORMATION: Bartonella quintana Antibody, IgG -- Less than 1:64 Negative: No significant level of Bartonella quintana IgG antibody detected. 1:64 - 1:128 Equivocal: Questionable Presence of Bartonella quintana IgG antibody detected. Repeat testing in 10-14 days may be helpful. 1:256 or greater Positive: Presence of IgG antibody to Bartonella quintana detected, suggestive of current or past infection. --A low positive suggests past exposure or infection, while high --positive results nay indicate recent or current infection, but is --inconclusive for diagnosis. Serocorversion between acute and BioReference Laboratories, Inc. 4S1 Edward H. Ross Dr I !Inwood Park, N3 07407 Specimen ID: 104364929 Date Of Report: 09/00/2017 ii:S0 Date Collected: 00/30/2817 11:58 Date Received: OS/30/2017 23:12 north Anorto &deem rtot JarneeMftneberimelAIL Page 8 Of 15 LaboratoryDbetter printed 09/68/2017 16:22 EFTA00299752 (58) . Performed by: BioReference _AscRATOR I Es an OPKO ment Comonny ORSHER, STUART C3070 - STUART ORSHER, III. 9 EAST 79TH ST, NEw YORK, NY 10021 Acct 4: (C3070) P: CLINICAL REPORT --convalescent sera is cons ered strong evidence of recent --infection. The best evidence for infection is a significant change --on two appropriately timed specimens where both tests are done in -.the same laboratory at the same time. --Test developed and characteristics determined by ARUP --Laboratories. See Compliance Statement A: aroplab.cca/CS EPSTEIN, 3EFFREY DOS: 01/20/1953 Age: 64 Y Sex: M U/FL: Bed: Rs: Patient ID: Address:9 EAST 71ST STREET, NEw YORK, NY 10021 SIEP C 43. tN0 Novi-Reactive Test Not Performed: ile were unable to perform the Hepatitis test(s) requested due to lipimia. Please resubmit a fasting specimen. HEP C Ab. (S/CO RATIO) (30) Performed by: MOP 500 Chipeta Way Salt Lake City, UT 84108 Viracor Eurofins Clinical Diagnostic 1001 NW Technology Drive Lees Summit, MO 64886 PIP <0.80 . Test Not Performed: One or more components were not available to perform calculation. H.PYLORI (IgG, IgA, IgM) REFERENCE RANGES RESULT (UNITS) INTERPRETATION <0.89 NEGATIVE 0.89.0.99 EQUIVOCAL >0.99 POSITIVE NOTE: This is a screening test for H.PYLORI. The diagnosis of gastritis and peptic ulcers should be assessed with the patients medical history and clinical symptoms. Results in the equivocal range should be rechecked with a now specimen in 2.5 weeks. NOTE: The H. Pylori, IgM test was developed and its performance characteristics were determined by BioReference Laboratories. It has not been cleared by the U.S. Food and Drug Adminis- tration. the FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. This lab has been approved by CLIA 88 and designated as a high complexity laboratory and is qualified to perform this test. ASSAY INFORMATION: Method ELISA NOTE: A result of equivocal or positive for B.burgdorferi (Lyme Ab) should not be interpreted without supplemental Western Blot testing. "Lyme Antibody ranges (IgG/IgM)*s <0.91 A Negative 0.91-1.09 = Equivocal lioReference Laboratories. Inc. 481 Edward H. Ross Dr I Elmwood Park. N3 07467 FINAL REPORT imen ID: 104364919 to Of Report: 09/08/2017 11:30 Date Collected: 08/30/2017 11:58 Date Received: 88/30/2017 23:12 North America Eastern lime JanwmcnielsbemperNUO. Page 9 of 15 Laboratorytlinctor Printed 69/08/2617 16:22 EFTA00299753 BioReference FINAL REPORT 3 R : ES A 4);71.(C7Healn Cornonny ORSHER, STUART C3070 - STUART ORSHER, N.O. 9 EAST 79TH ST, NEW YORK, NY 10021 Acct 4: (c3070) P CLINICAL REPORT Marker Vice. NO I , EPSTEIN, 3EFFREY 0436: 01/24/1953 Age: 64 Y Sex: m U/FL: Bed: Rm: Patient ID: Address:9 EAST 71ST STREET, NEW YORK, NY 10021 P: >1. Positive Hepatitis 8 Result Interpretation (for reference use only) LX/EA• Acute Past Chronic HBV HBeAg HBeAg HEP.R.CORO HEP.B.CORE AB. H6eAb HBsAb +/- 'Late Incubation/Early Acute MOTE: In remote past infection, HBsAb level may be Negative or Nom-Reactive in sore patients. +/- BikgdOEEN Positive • Neg4<1:80 !du ... 0.2 <0.5 :ESR (SNI-Rate,' 15 <21 EDUC '' Ado TNP >5.38 __ .. mg/di an/hr ng/mL . . Specimen ID: 104364919 Date Of Report:ea/es/2017 11:30 Date Collected: 08/30/2017 11:58 Date Received: 08/30/2017 23:12 North America Eastern Time Test Not Performed: Specimen rejected for testing due to moderate or marked hemolysis. Folic Acid Range Normal Borderline deficient Deficient Excessive units (ng/.L) >5.38 3.38-S.88 0.36-3.37 >24.00 iii-912 PgJEL . . . ! Test Not Performed: Specimen rejected for testing due to moderate or marked .! histolysis. 250X, VITAMIN D TNP Test Not Performed: unable to perform testing, specimen is LIPEIMIC. VITAMIN 0,25-OH TEST INPORHATION Range (ng/mL) <20.0 20.0-31.9 32.0.100.0 )100.0 CV17 $1;WOCIPREOCT •.• Two . Test Not Performed: Unable to perform testing, specimen is LIPEMIC. BioReference Laboratories, Inc. eel Edward H. Ross Dr I Elmwood Park, 47 07407 Suggested Interpretation Deficient Insufficient Sufficient Possible Adverse Effects 19.9-79.3 pg/iL JammsWeisbergmrh1D. Page 10 of 15 laborMoryDiredor Printed 09/08/2017 16:22 EFTA00299754 BioReference FINAL REPORT - A 9 09ATOR i ts en C7S2PCC2 Health Ccrnpnny ORSHER, STUART C1078 - STUART ORSHER, M.D. 9 EAST 79TH ST, NEW YORK, NY 10021 ACCt *: (C3078) P: NO HUMPS VIRUS Ab.(igG) 3.07 KOOTICUICD1 IIIII EPSTEIN, JEFFREY DOS: 01/20/1953 Age:64y Sex: M U/FL: Bed: Rm: Patient ID: Addresa:9 EAST 71ST STRICT, NEW YORK, NY 10021 P: Immunew>1.89 Specimen ID: 184364919 Date or Report: 09/88/2017 11:se Date Collected: 08/30/2017 11:58 Date Received: 08/30/2017 23:12 North Americo Eastern Time RANGES FOR LEAD, BLOOD Reference Range (ug/dL) Adult/Child <5.0 Occupational <40.0 NOTE: Lead risk guidelines conform to CDC Guidelines. BioReference is an OSHA-APPROVED lab for lead testing. NOTE: Blood lead levels in the range 5.0-9.9 ug/dL have been associated with adverse health effects in children aged 6 years end younger. NOTE: All Lead results m/>5.8 ug/dL are confirmed by repeat analysis. NOTE: Capillary and microtainer blood levels 2/>5.0 ug/dL may be due to contamination from lead found on the finger surface and requires confirmation on venous blood. NOTE: This test for LEAD was developed and its performance characteristics were determined by BioReference Laboratories. It has not been cleared by the U.S. Food and Drug Administration. TM FDA has determined that such clearance or approval is not necessary. This test Is used for clinical purposes. It should not be regarded as investigational or for research. This lab has been approved by CLIA 88 and designated as a high complexity laboratory and is qualified to perform this test. ASSAY INFORMATION: ICP-MS Immunotyping, Serum THY Negative NOTE: Specimen submitted is LIPEMIC. This may cause inaccurate results. Please RESUBMIT a fasting specimen at your earliest convenience. AeRclikii; BLOOD (30) 6-le ug/L INTERPRETIVE INFORMATION: Mercury, Blood Blood mercury levels predominantly reflect recent exposure and are most useful in the diagnosis of acute poisoning as blood mercury concentrations rise sharply and fall quickly over several days after ingestion. Blood concentrations in unexposed individuals rarely exceed 28 ug/L. The provided reference interval relates to inorganic mercury concentrations. Dietary and non-occupational exposure to organic mercury fonts may contribute to an elevated total mercury result. Clinical presentation after toxic exposure to organic mercury say include dysarthria, ataxia and constricted vision fields with mercury blood concentrations from 20 to SO ug/L. Test developed and characteristics determined by ARUP Laboratories. 5te Compliance Statement aruplab.Com/CS kuw.aruplab.c08, Julio Delgado, MD - Lab. Director 8U8EOLA/MEASLES(IgG) 1.81 Immune-)1.09 BioReference Laboratories, Inc. 481 Edward H. Ross Dr I Elmwood Park, N) 07407 James Worsens, M.D. Page il of 15 Laboratory Director printed 09/08/2817 16:22 EFTA00299755 BioReference FINAL REPORT CIPKO ,.• 0 0 C C 2 ORSHER, STUART C3070 - STUART ORSHER, III. 9 EAST 79TH ST, NEW YORK, NY 10021 Acct #: (C3070) P; MD CLINICAL REPORT VARICELLA ZOSTER,Ie I EPSTEIN, JEFFREY DOB: 02/70/1253 Age: 64 V Sex: M U/FL: Bed: Rm: Patient ID: Address:9 EAST 71ST STREET, .VW YORK, NY 1e671 P: REFERENCE RANGE for Varicella-rester IgM Abs: Less than 0.91 Negative 0.91 - 1.09 Equivocal Greater than 1.09 Positive Results from any one IgN assay should not be used as a sole determinant of a current or recent infection. Because an IgM test can yield false positive results and low levels of IV antibody may persist for more than 12 months post infection, reliance on a single test result could be misleading. Acute infection is best diagnosed by demonstrating the conversion of IgG from negative to positive. If an acute infection is suspected, consider obtaining a new'specimen and submit for both IgG and IgM testing in two or more weeks. VARICELLA ZOS.(IgG) 3.46 Immune=>1.09 INP 13.0-85.0 pg/ed. Test Not Performed: Specimen rejected for testing due to moderate or marked hemolysis. .68.144i6io 04 TITER cle iRMBELLAAG . TNP Test ripe Performed: Specimeisrefected for testing due • hemblyils. . . . liTERST/gICH OF RESULTS FOR RUBELLA 10 ANTIBODY I . *milt! 1ZU/mL) Interpretation 4.5.0 Negative Non-Immune 5;0 n 9.9 Equivocal Retest > 9;0 Positive Immune interpreted as EQUIVOCAL indicate a level of antibody below the -Positive.(Immune) cut off. Repeat testing on a new specimen is Suggistkd tv assess antibody response after a booster shot or a viral Syndrome... • ASSAYINRadgilONt %Hotbed themilualmescence (Siemens Diagnostics) :AMR TITER (IFA) 1:160 III '1:50 ANA PATTERN = HOMOGENEOUS MD SPECKLED <1.4 IIJAIL Immuftem>9.9. BOA to moderate or marked Titer Specimen ID: 104364919 Date Of Report: 09/00/2017 11:3n Date Collected:OE/30/2017 11:53 Date Received: 00/3e/2017 23:12 North Americo Eastern Time J Antibodies To Association Frequency ate Screening test for SLOE In symptomatic patients. (Antinuclear A, 95.100% BioReference Laboratories, Inc. JarnenVeninberciprMI.D. Page 12 of 15 eel Edward H. Ross Dr I Elmwood Park, N] 07407 I Laboratory Director Printed 09/02/1017 14:71 EFTA00299756 Bio Reference FINAL REPORT LAIORATOR IES en C2PN<C2Heafth Company ORSHER, STUART C3070 - STUART ORSHER, 9 EAST 79TH ST, NEW YORK, NY 10021 Acct li iTh0 P: MO CLINICAL REPORT re assay ANA ANA ANA IIIII EPSTEIN, IEFFREY DOB: 01/20/1953 Age: 64 Y Sex: M U/FL: Bed: Rm: Patient ID: Address:9 EAST 71ST STREET, NEW YORK, NY 10021 P: Assist with diagnosis of Scleroderna (Systemic Sclerosis). Sjogren's Syndrome. Idiopathic Inflammatory Polymyositis or Dereatteyositis• IIIII Specimen ID: 104364919 Date Of Report: 09/08/2017 11:30 Date Collected:08/30/2017 11:58 Date Received: 08/30/2017 23:12 North America fasten, rime 6e -SON 40-78% 38.80% Antibodies to specific (Extractable) Nuclear Antigens (ENA)/Proteins dsONA Sm(Smith) SS A (R0) 55 8 (La) 55 B (La) scl-70 7o-1 Centromere US nRNP Histone Proteins Characteristic of SLE. Rare in other CTDs. Highly associated with active disease. Highly specific for SLE. Uncommon in other diseases. Associated with SLE, Neonatal Lupus and Sjogren's Syndrome. Associated with SLE. Associated with Sjogren's Syndrome. (anti DNA Topoisomerase) Associated with Diffuse Scleroderma and rarely co exists with anti-Centromere Abs which are associated with Limited SchrOderee Disease. Associated with Polymyositis or Dermatomyositis. Identified by staining pattern. Their presence is associated with CREST Syndrome (Limited Systemic Sclerosis). Used to categorize Mixed Connective Tissue Disease (MCTO). (Chromatin) Associated with drug induced LE. 25-05% 15-301 35-60% 15% 44-68% 34-40% 28-25% 88% High Correlation 98.100% . refmavanaugh,A(et al.):Guidelines for clinical Use of the Antinuclear Antibody Test and Tests for Specific Autoantibodies to Nuclear Antigens. Arch.Pathol Lab Med. Vol.124,2an 2040. PrivAO al rm€-i"(3t) PNEUMO Ab 1,10t.i-iiii ' - -- 1.4 ' <0.3 LO >1.3 - - '›i'i. ' --.. '' .ugiii. -.- . . . . • PNEUMO Ab TYPE 4 (ill — • . . . PNEUMO Ab TYPE 8 (58) 0.8 LO itli . . 0.4 LO. >1.3 — . . ug/mL ug/.L MEUSE Ab TYPE 9 UN(F (58) ONEUPO Ab TYPE 12 (12F) (58).. .. '' 0.4 LO >1.3 40.0 0 >1.3 '' '' - - PHEW/ Ab ISIPE•11. 5g5 23.2 liNgD710 Mi. TYPE -iii tisirj• tisj • • • • Isilrio :'WIWI-21Sr (ii) >1.3 0.8 Lo >1:S • • a. s LA 31:1- - • Ng/nn tag/8i 1PALuno Ab TYPE 26 (68) (58) • • iS:s• Lei >1i' " - ug/iL Newark 'TYPE 5 (58) 7.8 . . oNeUmo- Ati riot Si (7P) (58) 1.5 >1.3 . .. >1.3 0.4 LO >1.3 • • • ug2mi ug/ni —r-.- ug/mL niitump:Ab TYPE 56-(194—(556-- -----:---..- MUM° Ab TYPE 68 (9V) (58) Testing Performed At: Viracor Eurofins 1001 NW Technology Drive Lee's Summit. PO 64086 CLIA8 26D-0983643 toff; Byeati $$ - 2-23. . ug/L 1 . T eioaefereeee Laboratories, Inc. James Weisberger M.D. Page 13 of is 481 Edward H. Ross Dr I Ellwood Park. NI 07407 Laboratory Director printed 09/08/2017 16:22 EFTA00299757 BioReference FINAL REPORT LABORATOR ES an ['PAC(' Health Company ORSNER, STUART C3070 - STUART ORSHER, III. 9 EAST 79TH ST, NEW YORK, NY 10021 Acct (C3070) P. CLINICAL REPORT A.Phagocytophila LEG Ab (24) <1:64 8.Henselae IgG Ab (3) 1:64 * < 1:64 titer B.Henvelae ICIAb (3) <1:20 < 1:20 titer EPSTEIN, lEFEREY DOB: 01/20/1951 Age: 64 Y Sex: H U/FL: Bed: Rm: Patient ID: Address:9 EAST 7157 STREET, rev YORK, NY 20021 This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute Valencia. It has not been cleaned or approved by the US Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes. Interpretation (24) SEE NOTE ANTIBODY NOT DETECTED REFERENCE RANGE IgG <1:64 IgM <1:20 Anaplasna phagocytophtlum is the tick-borne agent causing Human Granulocytic Ehrlichiosis (HGE). PIGE Is distinct and separate from Hunan Monocytic Ehrlichiosis (HMG), caused by Ehrlichia chaffeensis. Serologic crossreactivity between A. phagocytophilum and E. chaffeensis is minimal (5-15%). This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Infectious Disease. It has not been cleared or approved by the U.S- Food and Drug Administration. The FDA has determined that such clearance or approval is not ' necessary. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes. Quest Infectious Disease 33688 Ortega Hwy (3) Performed by: (24) Performed by: Quest Diagnostics Nichols Institute of Valencia 27027 Tourney Road Valencia, CA 91355-5386 Quest Infectious Disease 33608 Ortega Highway San Juan Capistrano, CA 92675 'medical Director Hollis I. Batterman, MD (30) Performed by: ARLIP 580 Chipeta Way Salt Lake City, UT 84108 (58) Performed by: Viracor Eurofins Clinical Diagnostic BioReference Laboratories, Inc. 481 Edward H. Ross Dr I Elmwood Park. N1 07407 I .1 .1 Specimen ID: 104364919 Date Of Report: 09/08/2017 11:S0 Date Collected: 08/30/2017 11:58 Date Received: 08/30/2017 23:12 North AmartCO Eastern Timis ... •••••••••••••••• JmneeVielsbengera40, Page 14 of 15 labonnoryDnechw Printed 09/08/2017 16:22 EFTA00299758 BioReference FINAL REPORT LABCPATOR I ES sr OPKO Hewn Company 0 0 C ORSHER, STUART C2870 - STUART ORSHER, H.D. 9 EAST 79TH ST, NEW YORK, NY 18021 Acct M: (C3070) P: MO 1001 Nel Techno ogy Drive Lees Summit, m0 64006 INTERPRETATION OF RESULTS FOR RUOEOLA(MEASLES),MUMPS,VARICELLA VIRUS ASS. EPSTEIN, 1EFFREY DOB: 01/20/1953 Age: 64 y sex: m U/FL: Bed: Rm: Patient /0: dreSS:0 EAST 71ST STREET, NEW YORK, NY 10021 P: Range Interpretation < or . 0.90 Negative Non-Immune 0.91 - 1.09 Equivocal Retest > or 1.10 Positive Immune Results interpreted as EQUIVOCAL indicate a level of antibody below the positive (Immune) tut off. Repeat testing on a new specimen is suggested to assess antibody response after a booster shot or a viral syndrome. I NOTE: The following tests: SERUM SELENIUM, SERUM CHROMIUM, ARSENIC 81.000 and CADM/uM BLOOD were developed and their performance characteristics were determined by BioReference Laboratories. They have not been cleared by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. These tests are used for clinical purposes. They should not be regarded as investigational or for research. This lab has been approved by CLIA 88 and designated as a high complexity laboratory and is qualified to perform these tests. NOTE: The specimen submitted was MARKEDLY hemoly2ed. Some results may be affected. Please resubmit as needed. NOTE: Specimen submitted is L/PEMIC. This may cause inaccurate results. Please resubmit a fasting specimen at your earliest convenience. cities) ID: 184364919 Date Of Report: 09/00/2017 11:30 Date Collected: 08/30/2017 12:58 Date Received: 00/30/2017 23:12 North America Eastern Time Bioneference Laboratories, Inc. Jarnesweiaberge<1411). Page 15 of 15 461 Edward H. RoSS Dr I Elmwood Park, 10 07407 I Laboudor/Direotor Printed 09/08/2017 16:22 EFTA00299759